OpGen, Inc. (NASDAQ:OPGN – Get Free Report) shares passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.66 and traded as low as $2.52. OpGen shares last traded at $2.58, with a volume of 4,941 shares traded.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of OpGen in a research report on Saturday, May 25th. They issued a “sell” rating on the stock.
View Our Latest Analysis on OpGen
OpGen Price Performance
Institutional Investors Weigh In On OpGen
A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new stake in shares of OpGen, Inc. (NASDAQ:OPGN – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen as of its most recent SEC filing. Hedge funds and other institutional investors own 2.68% of the company’s stock.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Further Reading
- Five stocks we like better than OpGen
- Earnings Per Share Calculator: How to Calculate EPS
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What is a Low P/E Ratio and What Does it Tell Investors?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.